Global Peptic Ulcer Drugs Market Growth (Status and Outlook) 2025-2031

Global Peptic Ulcer Drugs Market Growth (Status and Outlook) 2025-2031

The global Peptic Ulcer Drugs market size is predicted to grow from US$ 18400 million in 2025 to US$ 23210 million in 2031; it is expected to grow at a CAGR of 3.9% from 2025 to 2031.

Peptic ulcer drugs are medications specifically designed to treat and manage peptic ulcers, which are sores that develop on the lining of the stomach, small intestine, or esophagus due to the erosion caused by stomach acid. These drugs work by reducing stomach acid production, protecting the stomach lining, or eradicating the bacteria Helicobacter pylori, which is commonly associated with ulcer formation. The main classes of peptic ulcer drugs include proton pump inhibitors (PPIs), such as omeprazole and esomeprazole, which effectively lower acid secretion by inhibiting the proton pumps in the stomach lining. H2-receptor antagonists, like ranitidine and famotidine, also reduce acid production by blocking histamine receptors on acid-producing cells. Additionally, antacids neutralize existing stomach acid to provide immediate relief from ulcer-related symptoms. Other medications, such as sucralfate, create a protective barrier over the ulcer to aid healing, and antibiotics are used in combination therapies to eradicate H. pylori. These drugs play a crucial role in alleviating symptoms, promoting healing, and preventing ulcer recurrence, significantly improving the quality of life for individuals suffering from peptic ulcers.

The main global Peptic Ulcer Drugs players include Takeda Pharmaceutical, AstraZeneca, Pfizer, Teva Pharmaceuticals, EA Pharma, etc. The top five Peptic Ulcer Drugs players account for approximately 43% of the total market. United States is the largest consumer market for Peptic Ulcer Drugs, accounting for about 30%, followed by Europe and China. In terms of type, Proton Pump Inhibitors is the largest segment, with a share over 68%. And in terms of application, the largest application is Hospital and Clinic, followed by Drugstore.

The market for peptic ulcer drugs is evolving rapidly, driven by advancements in treatment options, increasing prevalence of gastrointestinal disorders, and a growing focus on personalized medicine. Proton pump inhibitors (PPIs) continue to dominate the market due to their efficacy in reducing stomach acid production and promoting ulcer healing. However, there is a notable shift towards exploring alternative therapies and combination treatments to address issues such as antibiotic resistance and long-term PPI use side effects. H2-receptor antagonists remain relevant, especially for patients who experience fewer side effects or need cost-effective solutions.

Recent trends highlight a growing interest in novel drug formulations and over-the-counter (OTC) options, as well as an increased emphasis on targeted therapies that address specific causes of ulcers, such as Helicobacter pylori infection. The market is also seeing innovations in drug delivery systems and adjunctive therapies designed to enhance treatment outcomes and patient compliance. Furthermore, rising awareness and diagnostic advancements are contributing to early detection and management of peptic ulcers, further driving market growth.



LPI (LP Information)' newest research report, the “Peptic Ulcer Drugs Industry Forecast” looks at past sales and reviews total world Peptic Ulcer Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Peptic Ulcer Drugs sales for 2025 through 2031. With Peptic Ulcer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptic Ulcer Drugs industry.

This Insight Report provides a comprehensive analysis of the global Peptic Ulcer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptic Ulcer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptic Ulcer Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptic Ulcer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptic Ulcer Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Peptic Ulcer Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Proton Pump Inhibitors
H2-Antagonists
Antacids
Others

Segmentation by Application:
Hospital and Clinic
Drugstore

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Livzon Pharmaceutical
Jiangsu Aosaikang Pharmaceutical
CTTQ
Luoxin Pharmaceuticals
Takeda
Eisai
Jumpcan Pharmaceutical
Zhejiang Conba Pharmaceutical
Youcare Pharmaceutical
Chongqing Lummy Pharmaceutical
Huadong Medicine
Hansoh Pharmaceutical
CR Double-Crane
Hunan Warrant Pharmaceutical
Changzhou Siyao Pharmaceuticals
Chongqing Pharscin Pharmaceutical
Lionco Pharmaceutical
Jiangsu Wuzhong Pharmaceutical
Cisen Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.